Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NYSE: NUVB

Nuvation Bio Inc.

Healthcare | Biotechnology

No licensed closing price on file for NUVB. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (FY2025)$-0.60

Nuvation Bio Inc. (NYSE: NUVB) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 04:07 UTC.

What Nuvation Bio Inc. does

Nuvation Bio is a global oncology company founded in 2018 that develops therapies targeting validated cancer treatment challenges. The company employs medicinal chemistry expertise to design novel small molecules aimed at improving safety and efficacy compared to standard treatments, including an innovative drug-drug-conjugate platform. Its lead product, IBTROZI, was commercially launched in the U.S. following FDA approval for treating ROS1-positive non-small cell lung cancer, with additional approvals and commercialization partnerships established in Japan and China.

Summarized from Nuvation Bio Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (FY2025)$-0.60
Debt/equity0.98

Revenue, margins & earnings

FY2024: net loss $568M on revenue $8M$8MFY2024FY2025: net loss $205M on revenue $63M$63MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-08-21
  • 2026-08-21CHIEF SCIENTIFIC OFFICEROption exercise100,000$187.0K
  • 2026-08-21CHIEF SCIENTIFIC OFFICERStock Option (Right to Buy)Option exercise-100,000—
  • 2026-08-21CHIEF SCIENTIFIC OFFICERSale-100,000$709.2K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Nuvation Bio Inc. do?

Nuvation Bio is a global oncology company founded in 2018 that develops therapies targeting validated cancer treatment challenges.

When did NUVB last file with the SEC?

Nuvation Bio Inc.'s most recent SEC filing on record is a 8-K filed 2026-07-06. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 04:07 UTC. This page is also available as JSON at /api/data?ticker=NUVB and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for NUVB and 5,000+ tickers.

Create a free account — keep NUVB
For your agent
GET /api/data?ticker=NUVB

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt